Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 101-108 of 108 (Search time: 0.029 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformationKok, C.; Watkins, D.; Leclercq, T.; D'Andrea, R.; Hughes, T.; White, D.
2013NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisisWatkins, D.; Hughes, T.; White, D.; D'Andrea, R.
2015KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategyYeung, D.; Tang, C.; Vidovic, L.; White, D.; Branford, S.; Hughes, T.; Yong, A.
2018Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the Phase IIIb ENESTswift studyHiwase, D.; Tan, P.; D'Rozario, J.; Taper, J.; Powell, A.; Irving, I.; Wright, M.; Branford, S.; Yeung, D.; Anderson, L.; Gervasio, O.; Levetan, C.; Roberts, W.; Solterbeck, A.; Traficante, R.; Hughes, T.
2019Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemiaRoss, D.; Pagani, I.; Irani, Y.; Clarson, J.; Leclercq, T.; Dang, P.; McLean, J.; Saunders, V.; Carne, L.; Reynolds, J.; Ritchie, D.; White, D.; Branford, S.; Hughes, T.; Yong, A.
2018Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell linesLu, L.; Kok, C.; Saunders, V.; Wang, J.; McLean, J.; Hughes, T.; White, D.; White, D.
2014High plasma levels of TGF-α and IL-6 at diagnosis predict early molecular response failure and transformation in CMLNievergall, E.; Reynolds, J.; Kok, C.; Watkins, D.; Biondo, M.; Busfield, S.; Vairo, G.; Yeung, D.; Lopez, A.; Hiwase, D.; White, D.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
2018Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosisTvorogov, D.; Thomas, D.; Liau, N.; Dottore, M.; Barry, E.; Lathi, M.; Kan, W.; Hercus, T.; Stomski, F.; Hughes, T.; Tergaonkar, V.; Parker, M.; Ross, D.; Majeti, R.; Babon, J.; Lopez, A.